OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
KYMR$85.6259

KYMR.O

Biotechnology & Medical ResearchVerified

Kymira Inc. exhibits a strong liquidity position, with a current ratio of 10.47 and cash and equivalents amounting to $357.01 million, which significantly exceeds its total liabilities of $163.15 million. The company's price-to-book ratio of 4.46 suggests that the market is valuing the company at a premium to its book value, indicating investor confidence in its intangible assets and future earnings potential. Despite its strong liquidity, Kymira is currently unprofitable, with a net loss of $311.35 million and an operating loss of $349.40 million in the latest reporting period. The company's return on equity of -19.71% and return on assets of -17.86% highlight the challenges it faces in generating returns for shareholders and asset utilization. These metrics are below the industry median for profitability, indicating that Kymira is underperforming its peers in terms of financial efficiency and earnings generation. Kymira's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and could limit its growth potential in the long term. Looking ahead, Kymira is expected to continue its current trajectory of losses, with no significant revenue growth anticipated in the next fiscal year. The company's capital expenditure of $1.45 million and free cash flow of -$304.49 million indicate that it is investing in its operations but is not generating positive cash flow from operations. This suggests that Kymira is in a growth phase, relying on cash reserves to fund its operations and expansion. The risk assessment for Kymira indicates a low probability of liquidity and dilution risks in the near term, with no immediate filing-based flags detected. However, the company's high price-to-revenue ratio of 170.59 and negative EV/EBITDA of -19.14 suggest that the market is valuing the company based on future growth expectations rather than current earnings. This valuation could be sensitive to changes in investor sentiment or delays in product development. Recent events and filings do not indicate any material changes in Kymira's business operations or financial position. The company's strong analyst coverage, with 9 strong-buy and 13 buy ratings, suggests that the market remains optimistic about its long-term prospects. The mean price target of $118.71 and median price target of $119.50 indicate that analysts expect the stock to appreciate significantly from its current price of $85.62.

30-day price · KYMR-7.30 (-8.2%)
Low$76.87High$90.14Close$81.70As of28 May, 00:00 UTC
Profile
CompanyKYMR.O
TickerKYMR.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Kymira Inc. operates in the healthcare diagnostics industry, focusing on the development and commercialization of diagnostic tests and related technologies.

Classification. Kymira is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Kymira Inc. exhibits a strong liquidity position, with a current ratio of 10.47 and cash and equivalents amounting to $357.01 million, which significantly exceeds its total liabilities of $163.15 million. The company's price-to-book ratio of 4.46 suggests that the market is valuing the company at a premium to its book value, indicating investor confidence in its intangible assets and future earnings potential. Despite its strong liquidity, Kymira is currently unprofitable, with a net loss of $311.35 million and an operating loss of $349.40 million in the latest reporting period. The company's return on equity of -19.71% and return on assets of -17.86% highlight the challenges it faces in generating returns for shareholders and asset utilization. These metrics are below the industry median for profitability, indicating that Kymira is underperforming its peers in terms of financial efficiency and earnings generation. Kymira's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and could limit its growth potential in the long term. Looking ahead, Kymira is expected to continue its current trajectory of losses, with no significant revenue growth anticipated in the next fiscal year. The company's capital expenditure of $1.45 million and free cash flow of -$304.49 million indicate that it is investing in its operations but is not generating positive cash flow from operations. This suggests that Kymira is in a growth phase, relying on cash reserves to fund its operations and expansion. The risk assessment for Kymira indicates a low probability of liquidity and dilution risks in the near term, with no immediate filing-based flags detected. However, the company's high price-to-revenue ratio of 170.59 and negative EV/EBITDA of -19.14 suggest that the market is valuing the company based on future growth expectations rather than current earnings. This valuation could be sensitive to changes in investor sentiment or delays in product development. Recent events and filings do not indicate any material changes in Kymira's business operations or financial position. The company's strong analyst coverage, with 9 strong-buy and 13 buy ratings, suggests that the market remains optimistic about its long-term prospects. The mean price target of $118.71 and median price target of $119.50 indicate that analysts expect the stock to appreciate significantly from its current price of $85.62.
Key takeaways
  • Kymira Inc. has a strong liquidity position with a current ratio of 10.47 and $357.01 million in cash and equivalents.
  • The company is currently unprofitable, with a net loss of $311.35 million and an operating loss of $349.40 million.
  • Kymira's return on equity of -19.71% and return on assets of -17.86% indicate poor financial performance relative to industry peers.
  • The company's revenue is concentrated in a single business segment, increasing its exposure to market-specific risks.
  • Analysts have a positive outlook on Kymira, with a mean price target of $118.71 and 9 strong-buy ratings.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$39.2M
Gross profit
Operating income-$349.4M
Net income-$311.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$232.9M
CapEx-$1.4M
Free cash flow-$304.5M
Total assets$1.74B
Total liabilities$163.1M
Total equity$1.58B
Cash & equivalents$357.0M
Long-term debt$3.3M
Valuation
Market price$85.62
Market cap$7.04B
Enterprise value$6.69B
P/E
Reported non-GAAP P/E
EV/Revenue170.6
EV/Op income
EV/OCF
P/B4.5
P/Tangible book4.5
Tangible book$1.58B
Net cash$353.7M
Current ratio10.5
Debt/Equity0.0
ROA-17.9%
ROE-19.7%
Cash conversion75.0%
CapEx/Revenue-3.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricKYMRActivity
Op margin-891.1%-227.5% medp25 -1250.6% · p75 -3.5%below median
Net margin-794.0%-194.5% medp25 -1233.8% · p75 0.8%below median
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-3.7%-8.2% medp25 -35.2% · p75 -2.5%above median
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Mean price target118.71 USD
Median price target119.50 USD
High price target140.00 USD
Low price target91.00 USD
Mean recommendation1.65 (1=strong buy, 5=strong sell)
Strong-buy count9.00
Buy count13.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-3.47 USD
Last actual EPS-3.69 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 15:34 UTC#f6cfd275
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 09:21 UTCJob: 8dda25c2